Cogent Biosciences director granted 17,901 stock options

Cogent Biosciences director Matthew Ros received a stock option grant, not an open‑market trade.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cogent Biosciences director Matthew Ros received a stock option grant, not an open‑market trade. He was awarded options for 17,901 shares of common stock at an exercise price of $31.98 per share, expiring on June 9, 2036. The option vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, conditioned on his continued service to the company through that date.

Insider Trade Summary

Grant/Award: 17,901 shares

Grant/Award 1 txn

Insider Ros Matthew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,901	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,901 contracts (Direct)

Footnotes (1)

F1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Key Figures

Option shares granted: 17,901 shares Exercise price: $31.98 per share Total derivative shares after grant: 17,901 shares +1 more

4 metrics

Option shares granted 17,901 shares Stock Option (Right to Buy) grant to director Matthew Ros

Exercise price $31.98 per share Conversion or exercise price of stock option

Total derivative shares after grant 17,901 shares Total options held following transaction

Option expiration date June 9, 2036 Expiry of stock option grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting of Stockholders financial

"earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders"

vesting financial

"This stock option shall vest in full upon the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cogent Biosciences (COGT) director Matthew Ros report in this Form 4?

Director Matthew Ros reported receiving a stock option grant. The award covers 17,901 shares of Cogent Biosciences common stock as a compensation grant, rather than an open‑market purchase or sale, and is documented as a derivative acquisition on the Form 4.

How many Cogent Biosciences (COGT) shares are covered by Matthew Ros’s new stock option?

The new stock option covers 17,901 shares of Cogent Biosciences common stock. This entire amount was granted in a single award and represents Ros’s total derivative holdings following the transaction reported in this Form 4 filing.

What is the exercise price of Matthew Ros’s Cogent Biosciences (COGT) stock option?

The exercise price of the stock option granted to Matthew Ros is $31.98 per share. This means he can buy Cogent Biosciences common stock at $31.98 if and when the option becomes vested and he chooses to exercise it.

When do Matthew Ros’s Cogent Biosciences stock options vest according to the filing?

The stock options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Vesting requires that Matthew Ros continue serving Cogent Biosciences through whichever of those dates occurs first.

When do the Cogent Biosciences (COGT) stock options granted to Matthew Ros expire?

The stock options granted to Matthew Ros expire on June 9, 2036. After that expiration date, he would no longer be able to exercise the options to purchase Cogent Biosciences common stock at the stated exercise price.

Is Matthew Ros’s Form 4 transaction a market buy or sell of Cogent Biosciences (COGT) shares?

The Form 4 reflects a grant of stock options, not a market buy or sell. It is recorded with transaction code A, indicating a grant, award, or other acquisition as part of his compensation rather than an open‑market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/11/2026 - 04:30 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ros Matthew

(Last)

(First)

(Middle)

C/O COGENT BIOSCIENCES, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cogent Biosciences, Inc. [ COGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$31.98	06/09/2026		A		17,901		⁽¹⁾	06/09/2036	Common Stock	17,901	$0	17,901	D

Explanation of Responses:

1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

	/s/ Evan D. Kearns, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR